News

News: CMN Weekly (22 October 2021)

Some of the best links we picked up around the internet

By: Karen O'Hanlon Cohrt - Oct. 22, 2021

Top picks

Industry

Research

  • New research from Princeton University, University of Californa San Francisco, Massachussetts Institute of Technology and Tessera Therapeutics details a novel method called Repair-seq that measures the effects of thousands of genetic perturbations on mutations introduced at targeted DNA lesions, to reveal in exquisite detail how genome editing tools work. The findings were published in Cell earlier his week.
  • A team at University of Massachussetts Medical School has explored chemical modifications to double-stranded and single-stranded DNA repair genome-editing templates. They describe several 5′-terminal modifications including the incorporation of triethylene glycol (TEG) moieties, that consistently increased the frequency of precision editing in the germlines of three animal models (Caenorhabditis elegans, zebrafish and mice) and in cultured human cells. The findings were published in eLife this week.

Reviews

Huh, heh, wow

  • Should we resurrect the woolly mammoth? Harvard bioscience company Colossal is planning to use CRISPR to resurrect the long-time extinct woolly mammoth. This brief piece looks at the scientific approach and movitation behind the proposal.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN WeeklyHashtagBeam Therapeutics Inc.HashtagCellectis S.A.HashtagCRISPR Therapeutics AGHashtagEditas Medicine, Inc.HashtagIntellia Therapeutics, Inc.HashtagPrime MedicineHashtagSana Biotechnology

News: News: CMN Weekly (22 October 2021)
CLINICAL TRIALS
Sickle Cell Disease, SCD
Sponsors:
Beam Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Hereditary Angioedema, HAE (NCT05120830)
Sponsors:
Intellia Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Acute Myeloid Leukemia, AML, (NCT05066165)
Sponsors:
Intellia Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine